Apellis Stock Down Despite Q3 Earnings and Revenues Beat Estimates

Key Takeaways Apellis posted Q3 EPS of $1.67, beating estimates, versus a loss of 46 cents a year ago.Revenues more than doubled to$ 458.6M, lifted by a $275M upfront payment from Sobi.Syfovre sales fell 1% year over year, missing expectations and weighing on investor sentiment.Apellis Pharmaceuticals (APLS) reported third-quarter 2025 earnings of$ 1.67 per share, beating the Zacks Consensus Estimate of $1.03 per share. The company had incurred a loss of 46 cents in the year-ago quarter.Total revenues in th ...